Alcon is downgraded to a hold from my buy rating in fall 2023, after it has gone up +18% since then and now appears ...

Attorneys for Musk intend to move to dismiss a suit that accuses the billionaire and Tesla of violating 'Blade Runner' IP ...

A judge has ruled against investor Alcon Research on the matter of blocking investee Aurion Biotech from debuting on the ...

Alcon Research LLC lost its court bid Tuesday to veto a public listing by Aurion Biotech Inc., a business it’s backing, but ...

Learn more about whether Alcon Inc. or Insulet Corporation is a better investment based on AAII's A+ Investor grades, which ...

Learn more about whether Alcon Inc. or Hologic, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

KeyBanc analyst Brett Fishbin revised the price target for Alcon Inc. (NYSE: NYSE:ALC) to $105.00, down from the previous target of $107.00, while continuing to endorse the stock with an Overweight ...

Aurion Biotech, Inc. plans $100M IPO for corneal disease treatments, limited competition, Phase 1/2 trials underway with ...

Cell therapy company Aurion Biotech is moving forward with plans to IPO despite a pending lawsuit from one of its existing ...

Analyst David Saxon from Needham maintained a Buy rating on Alcon (ALC – Research Report) and decreased the price target to $106.00 from ...

Elon Musk’s lawyers plan to ask the court to drop a case against him and his company. The case claims that Musk, who leads ...